
Conference Coverage
about 15 hours ago
Novel RSV Therapy: Addressing a Clinical NeedLatest Content

Novel RSV Therapy: Addressing a Clinical Need

Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants

Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Shorts










Videos
Contagion Digital Edition









All News

Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.

In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.

CDC lists 5 active multistate outbreaks tied to oysters, raw milk cheese, sprouts, and pet turtles, with recalls in effect for 4 of them.

Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.

Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.

MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.

Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.

The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.

Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

Oral pritelivir improved lesion healing and cut hospitalizations from 76% to 29.4% vs investigator's choice therapy in immunocompromised patients with refractory HSV.

Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.

Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.



















































































































































































